Rein Therapeutics Inc. (RNTX) Financials

RNTX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 26.3 million 14.7 million
Dec. 31, 2025 24.2 million 7.2 million
Sept. 30, 2025 53.7 million 7.5 million
June 30, 2025 57.5 million 54.5 million

RNTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -3.4 million 156000
Dec. 31, 2025 -3.2 million 257000
Sept. 30, 2025 -3.5 million 1.4 million
June 30, 2025 -6.4 million 256000

RNTX Net Income

No data available :(

RNTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 4.4 million - -
Dec. 31, 2025 3.2 million - -
Sept. 30, 2025 4.0 million - -
June 30, 2025 5.7 million - -

RNTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 30.4 million
Dec. 31, 2025 25.4 million
Sept. 30, 2025 26.4 million
June 30, 2025 24.2 million

RNTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 3.1 million 2.2 million -
Dec. 31, 2025 - 2.0 million 2.0 million -
Sept. 30, 2025 - 1.7 million 3.8 million -
June 30, 2025 - 4.3 million 2.6 million -

RNTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - 1000

RNTX

Price: $0.79

52 week price:
0.79
2.18

Earnings Per Share: -1.90 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 27.7 million

Links: